-

Hologic Board Member, Sally W. Crawford, Recognized As NACD Directorship 100™ Honoree

--The 16th Annual List Recognizes the Most Influential Corporate Directors and Governance Experts--

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that Board of Director's member, Sally W. Crawford, has been recognized by the National Association of Corporate Directors (NACD) as part of its 2022 NACD Directorship 100™ — honoring the most influential peer-nominated leaders in the boardroom and corporate governance community.

“Sally is truly deserving of this honor and her invaluable leadership, dedication and expertise continue to contribute significantly to Hologic and our purpose – to enable healthier lives everywhere, every day,” said Steve MacMillan, Hologic’s chairman, president and CEO. “We are extremely grateful for her insightful and trusted guidance as Lead Independent Director, chair of our Nominating and Corporate Governance Committee and a member of our Compensation Committee.”

Now in its 16th year, the NACD Directorship 100 awards recognize peer-nominated leading directors and governance professionals. Honorees are evaluated in four key categories: integrity, mature confidence, informed judgment, and high performance standards. A selection committee reviews the nominees’ histories of advancing board performance and leading corporate governance practices in accordance with established NACD principles. The principles are a framework that encourages excellence in areas that include risk oversight, corporate strategy, compensation, and transparency.

“The NACD Directorship 100 continues to honor those who have demonstrated exemplary board leadership and innovation in corporate governance,” said Peter R. Gleason, NACD president and CEO. “We honor these individuals’ forward-thinking minds and their ability to lead their board and organizations to current and future success.”

The complete list of the 2022 NACD Directorship 100 is available at https://directorship100.nacdonline.org/honorees/2022.

About Hologic, Inc.

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

About NACD

For more than 40 years, NACD has been on the leading edge of corporate governance, setting standards of excellence that have elevated board performance. NACD arms today’s directors with insights and education that drive their mission forward, while preparing a new generation of boardroom leaders to meet tomorrow’s biggest challenges. NACD is a community of more than 23,000 directors driven by a common purpose: to be trusted catalysts of economic opportunity and positive change—in businesses and in the communities they serve. To learn more about NACD, visit nacdonline.org.

SOURCE: Hologic, Inc.

Contacts

Hologic
Jane Mazur
Vice President, Corporate Communications
508.263.8764 (direct)
585.355.5978 (mobile)
jane.mazur@hologic.com

Ryan Simon
Vice President, Investor Relations
858.410.8514
ryan.simon@hologic.com

NACD
Shannon Bernauer
sbernauer@nacdonline.org
(571) 367-3688

Hologic, Inc.

NASDAQ:HOLX

Release Summary
Hologic Board Member, Sally W. Crawford, Recognized As NACD Directorship 100™ Honoree
Release Versions

Contacts

Hologic
Jane Mazur
Vice President, Corporate Communications
508.263.8764 (direct)
585.355.5978 (mobile)
jane.mazur@hologic.com

Ryan Simon
Vice President, Investor Relations
858.410.8514
ryan.simon@hologic.com

NACD
Shannon Bernauer
sbernauer@nacdonline.org
(571) 367-3688

More News From Hologic, Inc.

More Than One in Three U.S. Women Have Skipped or Delayed a Recommended Mammogram

MARLBOROUGH, Mass.--(BUSINESS WIRE)--More Than One in Three U.S. Women Have Skipped or Delayed a Recommended Mammogram Based on a New Survey of 1,000 Women...

New Data Shows Physicians Changed Extended Endocrine Therapy Recommendations for Over 40% of Patients Following Breast Cancer Index Testing

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. and its subsidiary, Biotheranostics, Inc., today announced newly published data in JAMA Network Open showing that Breast Cancer Index® (BCI®) test results led physicians to change their extended endocrine therapy recommendations for 42% of patients. In two-thirds of those cases, physicians changed their recommendation against extending treatment.1 The findings come from a large-scale BCI Registry Study conducted across multiple institutions at...

CE-IVDR Mark for Hologic’s Aptima® HPV Test Expanded to Include Self-Collected Sample Claim in Cervical Cancer Screening

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. announced today that its Aptima® HPV Assay received an expanded CE-IVDR marking in the European Union and the UK and is now approved for self-collected vaginal samples using the Aptima Multitest Specimen Collection Kit. Cervical cancer is the fourth most common cancer in women but is largely preventable through HPV vaccination and regular screening.1 Evidence shows that organized screening and early detection reduces deaths from cervical cancer...
Back to Newsroom